Literature DB >> 19936577

[Old and new anticoagulants. Antidotes and measures for acute hemorrhaging and urgent interventions].

M Lancé1, B Stessel, K Hamulyák, M A Marcus.   

Abstract

Anticoagulation medications are frequently used for primary and secondary treatment of several thrombo-embolic disorders. An important side effect of all anticoagulants is hemorrhagic diathesis which necessitates acute treatment, ideally using medicinal therapy with an antidote. Much experience has been gained in treating bleeding while on traditional anticoagulants, such as heparins and vitamin K antagonists by the use of antagonists. A multitude of factor-specific anticoagulants have recently been introduced or will soon receive approval. With this new generation of anticoagulants no valid laboratory parameters or effective antagonists are presently available. Due to a lack of adequate studies regarding acute treatment this can at present only be carried out on a symptomatic basis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19936577     DOI: 10.1007/s00101-009-1645-6

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  36 in total

1.  Protamine enhances fibrinolysis by decreasing clot strength: role of tissue factor-initiated thrombin generation.

Authors:  Vance G Nielsen
Journal:  Ann Thorac Surg       Date:  2006-05       Impact factor: 4.330

Review 2.  Desmopressin for minimising perioperative allogeneic blood transfusion.

Authors:  P A Carless; D A Henry; A J Moxey; D O'Connell; B McClelland; K M Henderson; K Sly; A Laupacis; D Fergusson
Journal:  Cochrane Database Syst Rev       Date:  2004

3.  Ecarin chromogenic assay--a new method for quantitative determination of direct thrombin inhibitors like hirudin.

Authors:  U Lange; G Nowak; E Bucha
Journal:  Pathophysiol Haemost Thromb       Date:  2003 Jul-2004 Aug

4.  Future of oral antiplatelet therapy: four challenged hypotheses.

Authors:  Victor L Serebruany; Leonid M Makarov
Journal:  Thromb Haemost       Date:  2009-06       Impact factor: 5.249

Review 5.  Laboratory monitoring of anticoagulation: where do we stand?

Authors:  Armando Tripodi; Antonius van den Besselaar
Journal:  Semin Thromb Hemost       Date:  2009-03-23       Impact factor: 4.180

6.  Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives.

Authors:  Elsa P Bianchini; Judicael Fazavana; Veronique Picard; Delphine Borgel
Journal:  Blood       Date:  2010-11-03       Impact factor: 22.113

7.  Thrombin generation and bleeding in haemophilia A.

Authors:  K E Brummel-Ziedins; M F Whelihan; M Gissel; K G Mann; G E Rivard
Journal:  Haemophilia       Date:  2009-06-26       Impact factor: 4.287

8.  Apixaban or enoxaparin for thromboprophylaxis after knee replacement.

Authors:  Michael Rud Lassen; Gary E Raskob; Alexander Gallus; Graham Pineo; Dalei Chen; Ronald J Portman
Journal:  N Engl J Med       Date:  2009-08-06       Impact factor: 91.245

9.  Hemofiltration of recombinant hirudin by different hemodialyzer membranes: implications for clinical use.

Authors:  Kerstin Benz; Matthias A Nauck; Joachim Böhler; Karl-Georg Fischer
Journal:  Clin J Am Soc Nephrol       Date:  2007-03-21       Impact factor: 8.237

10.  Emergency reversal of antithrombotic treatment.

Authors:  Marcel Levi
Journal:  Intern Emerg Med       Date:  2008-11-12       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.